InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.016 -0.001 (-5.88%)+
Announcement
Release
12 Nov 2025 9:53AM
Price at Release
$0.017
Full Release
download
Summary
Neurotech International Limited, a clinical-stage biopharmaceutical company focusing on pediatric neurological disorders, announced that it has received a $4.73 million R&D tax incentive refund for the financial year ending 30 June 2025. This refund is part of the Australian Government’s R&D tax incentive program, which offers a refundable tax offset of up to 48.5% for eligible activities. The funds will be used to advance Neurotech’s clinical development pipeline, particularly for its NTI164 cannabinoid therapy for disorders such as Autism Spectrum Disorder and spastic cerebral palsy, and as working capital. The announcement was authorized by the Managing Director of the company.
Key Points
  • Neurotech International Limited received a $4.73 million R&D tax incentive refund.
  • The refund is for the financial year ended 30 June 2025.
  • The Australian Government's R&D tax incentive provides a refundable tax offset up to 48.5%.
  • Funds will support clinical development and working capital.
  • Neurotech focuses on pediatric neurological disorders.
  • NTI164 therapy has shown promise in Autism Spectrum Disorder and other conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.